UNSPSC 51351903: Etynodiol

This classification denotes an ethynodiol analog, synthetic progestational hormone, and oral contraceptive with the molecular formula C20H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9E01C36A9S, chemically known as 19-norpregn-4-en-20-yne-3,17-diol, diacetate, (3beta,17alpha)- but generally known as etynodiol, which bears US NIH Compound Identifier 9270. European Medicines Agency schedules Etynodiol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07350MIG.

UNSPSC 51351903 Etynodiol is a Commodity code for a specific oral contraceptive active pharmaceutical ingredient. State and local governments procure etynodiol-containing products primarily through cooperative purchasing agreements that bundle generic pharmaceuticals and over-the-counter products into multi-source supply contracts. The work involves manufacturers or authorized distributors meeting rigorous regulatory, supply-chain, and technical requirements—cGMP certification, Drug Supply Chain Security Act compliance, National Drug Code and SKU documentation, and established relationships with authorized wholesalers. Issuing bodies are primarily state health agencies and multistate cooperative purchasing organizations administering agreements that serve state facilities, county health departments, and other participating jurisdictions across multiple states. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is a major repeat buyer under this code, using cooperative vehicles to aggregate demand across member states including Oregon and to negotiate volume pricing through established pharmaceutical wholesalers.

MMCAP issued a Request for Proposal (S1070000015802) on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, with a response deadline of March 26, 2026. The contract requires vendors to maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC), certify cGMP and DSCSA compliance, and submit detailed product specifications including NDC codes, packaging configurations, and manufacturing locations. Pricing is weighted at 75 percent of the evaluation, with administrative fees of 3 percent on all contract purchases. The resulting contracts are effective July 1, 2026 and run two years with optional extensions, with awarded vendors available to participating state and local facilities nationwide. No specific set-aside designations are identified in the RFP documentation.